Our data give evidence that CXCR3 ligands exhibit pronociceptive properties and play an important role in the initiation, development and maintenance of neuropathic pain. Moreover, intrathecal administration of each CXCR3 ligand induced hypersensitivity reactions in naive mice and of its neutralizing antibodies diminished neuropathic pain syndrome in CCI-exposed mice. Furthermore, our results indicate that selective CXCR3 antagonist ( 7)-NBI-74330 reduced the neuropathic pain-related behaviour and also enhanced morphine analgesic potency in CCI-exposed rats. Interestingly, our data show that ( 7)-NBI-74330 administration diminished the spinal IBA1 and, in parallel, downregulated CXCL4, CXCL9 and CXCL10. In addition, CXCR3 antagonist increased the spinal GFAP, what correlates with upregulation of CXCR3 and CXCL11. Moreover, in DRG (7 )-NBI-74330 did not change IBA1 and GFAP positive cells activation, however downregulated also CXCL9. CXCR3 and CXCL10 were co-localized predominantly with neuronal marker in the spinal cord. Summing up, chronic ( 7)-NBI-74330 intrathecal injection promotes beneficial analgesic effects in rat neuropathic pain model, as described in details in "Pharmacological blockade of CXCR3 by (7 )-NBI-74330 reduces
neuropathic pain and enhances opioid effectiveness -evidence from in vivo and in vitro studies" (Piotrowska et al., 2018 Table  Experimental factors The chemicals used were obtained from the following sources: ( 7)-NBI-74330 (Tocris, Warsaw, Poland) was reconstituted at 10 mg/mL in DMSO to prepare the stock solutions, which then was diluted to the doses used in the experiment (NBI, 10 μg/5 μL, i.t.) Morphine TEVA, Kutno, Poland was weighed and dissolved in water for injection to the dose used in the study (M; 2.5 μg/5 μL, i.t.) CXCL4, CXCL9, CXCL10, CXCL11, CCL21 (R&D Systems, USA) were reconstituted at 0.1 mg/mL in water for injection to prepare the stock solutions, which then was diluted to the doses desired in the experiment (2, 200 , and 400 ng/5 μl, i.t.) CXCL4, CXCL9, CXCL10, CXCL11, CCL21 neutralizing antibodies (R&D Systems, USA) were reconstituted at 2 mg/mL in water for injection to prepare the stock solutions, which then was diluted to the doses used in the experiment (4 and 8 mg/5 μL, i.t.)
Experimental features
The experiments were carried out according to IASP and NIH rules for the care and use of laboratory animals. Value of the data These data provide that CXCR3 ligands (CXCL4, CXCL9, CXCL10, CXCL11, CCL21) are important in the initiation, development and/or maintenance of neuropathic pain.
These data provide characterization of pronociceptive properties of CXCR3 ligands and cellular source of these factors.
The data support the development of research on neutralizing antibodies of CXCR3 ligands (CXCL9, CXCL10 and CCL21) in diminishing tactile and thermal hypersensitivity.
The data would be valuable for further studies on the effect of ( 7)NBI-74330 on glial cells modulations and the release of CXCR3 ligands and other pronociceptive factors.
These data could give a basis for further experiments on revealing the underlying mechanism of action of the (7 )NBI-74330 in reducing the symptoms of neuropathic pain and enhancing the effectiveness of morphine.
Data
Chronic intrathecal (7)-NBI-74330 administration significantly attenuated pain-related behaviour and enhanced the analgesic properties of morphine (Scheme 1A). The Western blot analysis provided evidence that CCI-induced the upregulation of microglial and astroglial markers, CXCR3 ligands (CXCL4, CXCL9, CXCL10) protein levels in the ipsilateral lumbar spinal cord and IBA1 and GFAP positive cells activation, and CXCL9 in the DRG. Interestingly, ( 7)-NBI-74330 significantly diminished microglial and increased astrocytes activation and downregulated the spinal expression of CXCL4, CXCL9 and CXCL10 in the spinal cord 7 days after CCI. In the DRG, ( 7)-NBI-74330 decreased CCIupregulated CXCL9 (Scheme 1B).
Experimental design, materials and methods

Animals
In our experiments we used male Wistar rats and Albino Swiss mice from Charles River (Sulzfeld, Germany)
Neuropathic pain model
Bennett model, recognized widely as CCI model due to its unilateral Chronic Constriction Injury to the right sciatic nerve in rats and mice (Scheme 2) [1-4].
Study design in rat neuropathic pain model
First stage of behavioural studies
The chronic administration of (7)-NBI-74330 (NBI, 10 μg/5 μl) or vehicle (V) were provided once a day 16 h (day 1) and 1 h (day 0) before CCI and for 7 next days (like maraviroc [4] ). On the 7th day post-CCI behavioural tests were conducted 120 min (von Frey test) and 125 min (cold plate test) after NBI or V administration and then 6 h (for Western blot analysis) after the last NBI or V injection the tissue was collected (Scheme 2A) [1] .
Second stage of behavioural studies
The co-administration of chronic (7)-NBI-74330 with opioids were performed. The group of repeatedly NBI-or V-treated rats received on the 7th day after CCI (approximately 180 min after NBI or V injection) a single injection of morphine (2.5 μg/5 μl), and then, the von Frey and cold plate tests were conducted. Abbreviations: CCI, chronic constriction injury; DRG, dorsal root ganglia; i.t., intrathecal; NBI, ( 7)NBI-74330; V, vehicle; M, morphine (Scheme 2B) [1] . The influence of single intrathecal administration of CXCL4, CXCL9, CXCL10, CXCL11, CCL21 on nociceptive transmission in naive mice.
Fourth stage of behavioural studies
The influence of single intrathecal administration of CXCL9, CXCL11, CCL21 neutralizing antibodies on pain-related behaviours in CCI-exposed in mice.
